End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
14.99 CNY | +0.20% | -0.60% | -0.99% |
29/04 | Jilin Aodong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
17/04 | Aodong Medicine's 2023 Profit Declines 18%; Revenue Up 20% | MT |
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach -100% by 2026.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- Revenue estimates are regularly revised downwards for the current and coming years.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-0.99% | 247.6Cr | C | ||
+29.98% | 68TCr | C+ | ||
+30.34% | 57TCr | B | ||
-3.52% | 36TCr | C+ | ||
+18.59% | 33TCr | B- | ||
+4.07% | 28TCr | C+ | ||
+16.21% | 24TCr | B+ | ||
+9.66% | 21TCr | B- | ||
-6.83% | 20TCr | A+ | ||
+7.09% | 17TCr | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 000623 Stock
- Ratings Jilin Aodong Pharmaceutical Group Co., Ltd.